Status:
TERMINATED
Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency
Lead Sponsor:
Southern Medical University, China
Conditions:
Renal Insufficiency,Chronic
Disease Progression
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The primary goal of the trial was to evaluate whether the optimal antiproteinuric doses of benazepril (an ACE inhibitor) or losartan (an ARB), as compared with their conventional doses, can safely imp...
Eligibility Criteria
Inclusion
- Serum creatinine concentration of 1.5 to 5.0 mg per deciliter (133 to 442 µmol/L)
- Creatinine clearance of 20 to 70 ml per minute per 1.73m2, with variations of less than 30 percent in the three months before screening evaluation
- nondiabetic renal disease
- Persistent heavier proteinuria (defined by urinary protein excretion of more than 1.0 g per day for three or more months without evidence of urinary tract infection or overt heart failure \[a New York Heart Association class of Ⅲ or Ⅳ\])
Exclusion
- Immediate need for dialysis
- Treatment with corticosteroids, non steroidal anti-inflammatory drugs, or immunosuppressive drugs
- Hyper-or hypokalemia (serum potassium concentration 5.6 mmol per liter or more，or 3.5 mmol per liter or less)
- Renovascular disease
- Myocardial infarction or cerebrovascular accident in the year preceding the trial
- Connective-tissue disease; and obstructive uropathy
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00338091
Start Date
January 1 2002
End Date
May 1 2006
Last Update
June 20 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renal Division, Nanfang Hospital,Southern Medical University
Guangzhou, Guangdong, China, 510515